Monjuvi: Targeted lymphoma therapy in the spotlight for U.S. patients

Responsible: ad hoc news B2B & Pro Desk. Reviewed prior to publication on June 13, 2026 at 4:34 PM ET. Details in the imprint.

Monjuvi is a prescription cancer medicine that is approved in the United States to treat certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), one of the most common and aggressive types of non-Hodgkin lymphoma. The drug, developed by MorphoSys AG together with partner Incyte, is given by intravenous infusion in combination with the immunomodulatory agent lenalidomide in patients who are not eligible for an autologous stem cell transplant. For U.S. hematologists and oncology centers, Monjuvi has become one of several targeted options for patients whose disease has not responded to prior therapies, sitting alongside antibody-drug conjugates and CAR-T cell treatments in later lines of care.

What Monjuvi does and how it works for DLBCL patients

Monjuvi (tafasitamab-cxix) is a humanized, Fc-modified monoclonal antibody that binds to the CD19 antigen on the surface of malignant B cells. By attaching to CD19, the drug helps the immune system recognize and destroy B cells through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis. This targeted approach allows clinicians to attack lymphoma cells with precision, while the combination with lenalidomide is intended to further stimulate immune activity against the cancer. According to the U.S. prescribing information, Monjuvi is indicated for adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, after at least one line of systemic therapy, in those who cannot receive autologous stem cell transplant.

The recommended dosing regimen in the U.S. consists of an initial, more intensive phase followed by a maintenance schedule. Treatment typically starts with Monjuvi given intravenously once a week for the first three 28-day cycles, along with lenalidomide taken orally on most days of each cycle, followed by a less frequent infusion schedule every two weeks in later cycles. If patients tolerate therapy and derive benefit, Monjuvi can continue as monotherapy after lenalidomide is stopped, until disease progression or unacceptable toxicity. Because infusions may last several hours and require close monitoring, the product is primarily administered in specialized infusion centers or hospital-based oncology clinics across the United States.

As with other targeted cancer therapies, side effects and safety measures play a major role in treatment decisions. The Monjuvi prescribing information lists common adverse reactions such as infections, infusion-related reactions, fatigue, musculoskeletal pain, diarrhea, cough, fever, peripheral edema and decreased appetite. More serious risks include neutropenia, thrombocytopenia and anemia, which can increase the risk of infections and bleeding. Patients are generally monitored with regular blood counts and evaluated for signs of infections or other complications throughout therapy. The label also recommends prophylactic measures such as vaccinations and infection surveillance according to institutional guidelines, reflecting the immunosuppressive nature of combination treatment in this patient population.

From a clinical efficacy standpoint, the approval of Monjuvi in the U.S. was based on data from the open-label L-MIND trial, which studied tafasitamab plus lenalidomide in adults with relapsed or refractory DLBCL who were ineligible for high-dose chemotherapy and autologous stem cell transplant. In that study, patients achieved an overall response rate that regulators considered clinically meaningful, with a subset reaching complete remission and some responses lasting beyond one year. While the trial was single-arm and relatively small compared with pivotal studies for newly diagnosed lymphoma, it addressed a group of patients with limited options and helped justify accelerated approval for this targeted regimen. In the broader treatment algorithm, Monjuvi is often viewed as an option for patients who may not be candidates for CAR-T cell therapy or who need an off-the-shelf alternative that can be started more quickly in community oncology settings.

On U.S. product materials, Monjuvi is positioned as a specialized, hospital-administered drug rather than a retail pharmacy product, with distribution managed through specialty distributors that supply oncology practices and infusion centers. Pricing is typically handled through buy-and-bill reimbursement models under Medicare Part B and commercial insurance plans, reflecting its status as an infused biologic medicine. Public price benchmarks indicate that Monjuvi, like many oncology biologics, is associated with high treatment costs per infusion cycle, though actual out-of-pocket costs for patients vary depending on insurance coverage, co-pay assistance programs and institutional contracts. U.S. payers often require prior authorization, and coverage policies may reference the FDA-approved indication, NCCN guidelines and patient eligibility criteria such as prior treatment history and transplant ineligibility.

For MorphoSys AG, Monjuvi represents a key marketed product in its oncology portfolio, particularly in the United States where it is commercialized alongside partner Incyte. The company has highlighted Monjuvi as a core asset in its hematology franchise and has pursued additional studies to explore longer-term outcomes and potential expanded use, although the current U.S. label remains focused on relapsed or refractory DLBCL after at least one prior therapy. Shares of MorphoSys AG (DE0006632003, ticker MOR) last traded on Nasdaq at a U.S.-dollar price that reflects market assessments of its hematology and oncology pipeline alongside existing commercial products.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.